Matthew Ros is COO at Epizyme, Inc. (EPZM). They have made 2 open-market trades across 1 company since 2018, most recently 2025-04-01.
CIK 0001673802
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EPZM | SELL · 10b5-1 | 2021-02-04 | 2021-02-05 | $11.21 | $10K | -4.0% | -19.3% | -38.8% |
| EPZM | SELL · 10b5-1 | 2021-01-25 | 2021-01-27 | $11.41 | $33K | -2.4% | -19.3% | -31.3% |
| EPZM | SELL · 10b5-1 | 2020-06-26 | 2020-06-30 | $16.15 | $44K | -7.2% | -13.1% | -24.6% |
| EPZM | SELL | 2020-06-18 | 2020-06-22 | $21.23 | $4.7M | -13.0% | -19.4% | -29.6% |
| EPZM | SELL · 10b5-1 | 2020-03-25 | 2020-03-26 | $15.28 | $19K | -11.1% | +3.2% | -2.7% |
| EPZM | SELL · 10b5-1 | 2020-01-24 | 2020-01-27 | $24.64 | $46K | +1.6% | +1.0% | -18.4% |
| EPZM | SELL · 10b5-1 | 2019-06-13 | 2019-06-14 | $12.10 | $14K | +9.4% | +16.2% | +3.3% |
| EPZM | SELL | 2018-02-05 | 2018-02-06 | $16.63 | $2.4M | +11.0% | +7.6% | -15.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.